Just another guy with a day job and an obsession with stocks... goal is to find stocks that are TURNING THE CORNER, where a good story and an interesting stock chart result in a high probability of large % gains. These stocks can typically achieve such momentum that alpha is generated in both bear and bull markets. I generally stick to under the radar growth and turnaround ideas, some of which may give investors time to establish a position. Ideally, I prefer to hold these companies medium to long term, but am not averse to selling shares if they become extremely overvalued or my thesis changes.
I continue to refine my strategy and risk management through sharing my ideas publicly and closely monitoring my positions. I rely on strong fundamental analysis, high conviction ideas (mainly long/a few shorts are possible when they meet my criteria), and preplanned allocations (% of portfolio) to avoid overconfidence, as the market eventually humbles us all from time to time. I also have a smattering of macro calls and contrarian positions as well. I have several screens that I use to come up with under the radar ideas, focusing on mainly growth and turnaround stocks with multiple upcoming catalysts.
Best Call: Celldex (established position between $2 and $5 and sold at $25 netting over 500% gain and bought my condo with proceeds)
Worst Call: Lpath (lost >80% after rec) ... a humbling reminder that my next call can always be a dud. This spurs me on to do the best DD that I can, while cutting losses and admitting my mistakes when wrong.
Lawrence is the Managing Director of Fuller Asset Management. He has 20+ years of experience managing investment portfolios and serving the needs of individual clients. He began his career as a Financial Consultant in 1993 with Merrill Lynch. He worked for First Union Brokerage, Morgan Stanley and ING in the same capacity before realizing his long-term goal of complete independence. He graduated from the University of North Carolina at Chapel Hill with a B.A. in Political Science in 1992.
Earned a Doctorate in Pharmacy (Pharm.D.) in 2010 and Pre-Pharmacy/B.S. in Molecular Biology in 2006. Over six years of direct experience in translational research in oncology investigating the molecular/cellular mechanisms of carcinogenesis focused on biomarker identification and validation working in a multi-disciplinary matrix environment across academia, contract research organizations and industry.
Analyst Tip Ranks: https://www.tipranks.com/experts/dr.-paul-nunzio-desantis%252C-pharm.d
Having always been a learning machine, I speak five languages, have worked as a sales agent, project manager, translator, computer consultant, software engineer, built a house with my own hands, published books and essays on literature, philosophy and art, have written for magazines of various kinds in different countries.
After retiring early in 2004, little by little, I have become a fund manager for some friends and myself, following the principles of value investing laid out by Benjamin Graham, Phil Fisher, Charlie Munger and Warren Buffett. You can read about my thoughts on a suitable portfolio structure for early retirees here.
My articles should not be considered to be any kind of investment advice. What suits me well is not necessarily good for others, as successful investing is somewhat like a marriage: If only one is perfect, the marriage won’t work. So please do your own research and remember Benjamin Graham's advice: “The investor’s chief problem — and even his worst enemy — is likely to be himself.”
I sincerely hope that my readers will ignore the Performance calculations provided by Seeking Alpha (although only to Pro subscribers, I believe). For reasons unknown to me, some of my European stock picks seem to be tracked inaccurately by Seeking Alpha's system. Spin-offs are not included in total return calculations and many of my correction requests didn't receive any answer at all. Moreover, my time frame almost never is as short as only 1 year (the maximum included in Seeking Alpha's table) and personally I consider the 1 year performance of my stock picks to be close to meaningless.
The Life Sciences Report features leading investment coverage of the life sciences sector, including biotechnology, pharmaceuticals, tools & diagnostics, and medical devices. A Streetwise Reports publication. www.TheLifeSciencesReport.com
I am an individual investor who has been actively involved in the healthcare and biotechnology space for over 15 years. I hold a PhD in the biomedical sciences and have worked in both large pharmaceutical and small biotech companies. I make investments based on the fundamentals of a company and if I believe they have a superior technology or products compared to the competition. I'm an investor who believes patience pays off.
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
I'm currently a resident Psychiatrist in Houston, Tx. I previously worked as an analyst in Dallas. I keep a value portfolio and speculative portfolio. In my value investing work, I use a valuation framework influenced by Joel Greenblatt, Peter Lynch, and Ben Graham. In my speculative portfolio, I speculate both long and short high-multiple momentum stocks and macro plays, using a framework influenced by George Soros, Stan Druckenmiller, and Paul Tudor Jones.
Beacon VP is a multidisciplinary team of Harvard/MIT scientists who are passionate about transforming scientific insights into actionable investment ideas.
Beacon VP invests in the scientific foundation of biotech firms, with a focus on drugs and devices progressing through the FDA review process.
Our philosophy is: "The business value of small to mid-cap life science companies depends on the underlying science of its drugs. We assess its safety and efficacy, then buy low and sell high".
Micro cap investor interested in value stocks. I prefer to research and write about emerging growth companies that I believe have paradigm shifting technologies or potential near-term catalysts. I tend to avoid Biotech's.
I have been trading part time for the past 10 years, focusing on swing trades and identifying how different stocks will "inhale and exhale" through the market. My primary targets are in the $2-$10 range, averaging over 2 million shares traded daily, and looking for an upswing. My goal is to average 10% per month, but will hold on for the long run with stocks that I believe in.
Individual investor focused on domestic and international microcap stocks. I follow a value investing philosophy and look for companies with attractive prospects that I gauge as undervalued either by investor neglect or temporary problems affecting sentiment. I pay a lot of attention to the competitive advantages of companies and the incentives of insiders - trying to go beyond the numbers to find opportunities not clear to others. I am also constantly looking for special situations - spinoffs, dispositions, management overhauls, etc. - that I feel will cause a company's future to be a lot different than it’s past. I present all my ideas on my blog @ moatology.com
Beyond microcap investing, I am a fitness enthusiast, enjoy a weekend round of golf, and travel as often as I can.
Shane Skinner has invested in biotech companies for almost 20 years and placed over $2.6 million in biotech stock trades in 2013. He has held various financial leadership positions over the past 17 years throughout the United States and Europe including Chief Financial Officer. Shane graduated from Pepperdine University with an MBA, York College with a bachelor's degree in accounting, and is a licensed CPA. He was a collegiate soccer and rugby player and still plays in recreational leagues in Seattle. He has a wife, son, and one on the way!
Full Time Trader. Long / Short Equity Options.
I am a technical trader that tries to find the sweet spot between technical set up, institutional option order flow, and fundamentals.
I am especially interested in market / trading psychology and its impact on our performance.
To receive my free daily market message that highlights the biggest and most notable trades in the option market, email me at : email@example.com
I will be glad to include you!
I am an independent trader. I have been trading my own money for over 20 years.
I am focused on finding growth stocks that are priced like value stocks or stocks that are misunderstood or under followed. Generally, I buy stocks where I feel like my chances of losing money are low, but still offer the possibility of large gains. This almost always leads me to small and microcap cap stocks.
I joined Seeking Alpha to share some of my ideas with others. I hope they are profitable.
Please do your own due diligence and do not blindly buy stocks on Seeking Alpha articles alone (including mine).
My name is Joe and I day trade. I specialize in break out stocks. I find stocks before they gain momentum. I have over 8 years of experience in trading stocks under $5.00 a share. I am not a certified financial consultant or investment adviser. I day trade and share my experience with those who care to follow along. All my trades are transparent and I share all my profits as well as my losses. We never progress forward if we do not learn from our mistakes.
I created a following on social media called PSProfits with the vision of creating a community for regular hard working Americans that want an extra means of income to get ahead of keeping up with the bills. I'm a regular hard working middle class guy and a veteran. I started with penny stocks in 2007 when I was deployed overseas. I didn't want my hard earned money sitting in a bank collecting next to nothing. I made it a goal of mine to educate myself on day trading and short term, high yield investments. I want to share my exciting gains in the stock market with other hard working Americans like you and I. I invest my time and my own money in the stocks I share and blog about.
We have investment positions in some of the securities we write about, and our positions are subject to change at any time. Nothing here is to be deemed a solicitation for investment nor investment advice. Please read our full legal disclaimer available on our blog. http://lazarusip.blogspot.com/
George Nikolaou, President and Founder of Market Research, LLC has more than 15 years experience in stock market analytics and personal investing.
My investment fund in California specializes in researching small to mid cap companies in the health care sector. Our focus and strategy has and always will be to discover and invest in companies that have low risk and provide significant upside value.
10 years investing in $10 or less stocks. My portfolio has grown from an initial $4K investment to well over a million in that period of time. I specialize in identifying under-the-radar, unloved stocks with great upside.
An experienced research and advisory team of Traders and Forecasters have combined to offer free services and alerts at StockReversals.com, A free growth stock profile, research and alert service with benefits. Go to the website to subscribe for free. We also offer StockReversalsPremium.com which offers a combination of long term growth stock profiles with massive upside potential, plus swing position trading (days to 8 weeks holding).
Seeking Alpha Certified and Frequent Contributor to numerous financial websites. We specialize in behavioral analysis as it applies to market patterns and reversal trends. These trends happen over short term, intermediate, and long term time frames. We help our free subscribers with Business Disruptor growth stocks that crush the market. Sample picks include FB, YY, DATA, INVN, SPCB, MOBI, CUR and many more. In 6 months we had 6 doubles, 1 triple, and 16 of 19 companies up 30-50% or more.
Our work centers around a combination of Elliott Wave Theory, Technical Analysis, Human Behaviors, Sentiment, and Business Disruption analysis.
We have advisory clients from around the world. South Korea, Australia, Canada, Sweden, Germany, The Netherlands and of course the U.S.
We give away our service for free because of the laws of nature which we have on our website:
“The possession of knowledge, unless accompanied by the manifestation and expression in sharing is a vain and foolish thing. The Law of Use is universal, and he who violates it suffers by reason of his conflict with natural forces.”
Join us today at stockreversals.com and sign up for free.
Analyst and Fund Manager with almost 20 years investment experience. Coverage includes a variety of industries, with a focus on technology.
Particularly focused on value stocks, poorly understood or under-followed situations, and contrarian perspectives.
Primarily invest in special situations with value that is poorly understood or not fully appreciated, or where we believe there is a highly asymetric risk/reward profile. Also look for long/short ideas in mid/larger cap names where we believe we have a variant view, and the market is dramatically mispricing value.
Follow me on Twitter @valinsights
I'm a radiologist by trade, but the goal is to leverage that medical knowledge as a competitive advantage in the markets. I aim to include all of the following in my analyses to ensure high quality: 1) quantitative estimates; 2) new information or inferences that are not already disseminated throughout the market; and 3) hypotheses that are testable, i.e. can be proved right or wrong. I have a serious allergy to question marks and will never, ever include one in an article title.
My dream is to co-found a biotech and bring a cure from the lab to the bedside. In the meantime, saving lives in clinical practice is a perfectly acceptable alternative.
Please note that all opinions I express on this website reflect my personal beliefs only and are completely independent of my current or past employers and/or affiliated institutions.
I'm an independent equity researcher, writer and investor based in Amsterdam. My primary focus is on the micro-cap segment of the market. I also work for pension funds as a member of the Board and Investment Committee. Lastly, I enjoy soccer, sports in general and brewing the best coffee one can make at home.
Disclaimer and disclosure: It is probable that the author and his associates have a position in the subject securities consistent with the opinion expressed in this article and they reserve the right to buy and/or sell the securities mentioned in this article, at any time without further notice.
Zorro Trades attempts to utilize fundamental analysis to identify securities and then gain an idea of when to enter said security via technical analysis.